Loading stock data…
EQ
$2.70-0.07 (-2.53%)
After Hours$2.70-0.00 (-0.01%)· Last close Jun 9
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Equillium, Inc. in the Healthcare sector is trading at $2.70. Wall Street consensus targets $7.12 (8 analysts), implying a +163.9% move over the next 12 months. The stock is currently 22% below its 52-week high of $3.45, remaining 62.7% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +163.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$2.70
Potential Downside
0%
Whystock Fair Value$2.70
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinica...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-32.03%
Volume
Today's trading volume
433,191
Recent News
Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1
Equillium (NASDAQ:EQ) Chief Scientific Officer Stephen Connelly outlined new preclinical data during a company webinar focused on the relationship between the aryl hydrocarbon receptor, or AhR, and miR-124, a microRNA implicated in inflammatory disease biology. The presentation, titled “Insights to
Here’s What Roth Capital Thinks of Equillium (EQ) Stock
Equillium, Inc. (NASDAQ:EQ) is one of the 10 Best High-Risk Penny Stocks to Buy Right Now. On March 13, Roth Capital analyst Adam Walsh initiated coverage of Equillium, Inc. (NASDAQ:EQ), assigning a Buy rating and a price target of $12. The firm’s assigned price target suggests a compelling 458% upside from the current levels. The […]
Equillium Conference: EQ504 Targets Ulcerative Colitis Ahead of Mid-Year Phase 1 Start
Executives from Equillium (NASDAQ:EQ) outlined the scientific rationale and near-term development plans for its lead program, EQ504, during a recent fireside chat focused on immunology and inflammatory bowel disease (IBD). Positioning EQ504 in ulcerative colitis Company representatives described ul
Trending tickers: Intel, Tilray, monday.com, Equillium and AMC
The latest investor updates on stocks that are trending on Tuesday
BC-Most Active Stocks
Gibo Holdings Ltd. 239,477,124 0.049